1. Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Introduction

5. Pembrolizumab: KEYNOTE 012

6. Pembrolizumab: KEYNOTE 055

10. Case 1: 59-Year-Old Woman With Locally Advanced Hypopharyngeal Cancer

11. Case 1: First Steps

12. Case 1 (cont)

13. Case 1: Checkpoint Inhibition

14. Case 1: Follow-Up

15. Further Thoughts

16. Case 2: 44-Year-Old Man With Locally Advanced Tonsil Cancer

17. Significance of HPV

18. Case 2: Treatment

19. Case 2: Further Details

20. Addressing Patient Requests

21. Immunotherapy Clinical Trials in the Curative Setting

22. Immunotherapy Clinical Trials of First-Line Therapy in the Recurrent and/or Metastatic Setting

23. Other Immunotherapeutic Approaches Under Investigation

24. Thoughts for the Future

25. Conclusions

26. Abbreviations